Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
|
|
PROLUNG INC (LUNG)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/28/2022 |
8-K
| Quarterly results |
| 03/08/2022 |
8-K
| Quarterly results |
| 02/02/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data|
Docs:
|
"About IONIQ Sciences, Inc. IONIQ Sciences, Inc. is developing an advanced multi-cancer screening technology for early detection that has the potential to expand the therapeutic window, dramatically improve survivability and reduce the cost of healthcare. IONIQ Sciences operates at the confluence of its Electrical Impedance Analytics or bioimpedance technology and Artificial Intelligence . IONIQ Science’ s first product utilizing its proprietary analytic platform, the IONIQ ProLung Test™ for lung cancer, has been designated a Breakthrough Device by the U.S. FDA. For further information about IONIQ Sciences, Inc., please contact: Andy Robertson | 1-801-736-0729 | [email protected] IONIQ Sciences, Vice President of Business Development IONIQ Sciences, Inc. 350 W. 800 N., Suite 214 S..." |
|
| 10/07/2021 |
8-K
| Appointed a new director|
Docs:
|
"IONIQ Sciences Announces the Appointment of Aaron B. Dorny to its Board of Directors Salt Lake City, UT, October 7, 2021 – IONIQ Sciences, Inc. , is developing a rapid and non-invasive Multi-Cancer Screen for early detection that has the potential to expand the therapeutic window, dramatically improve survivability and reduce the cost of healthcare. Today IONIQ Sciences announced the appointment of Aaron B. Dorny to its Board of Directors. Mr. Jared Bauer, CEO, stated, “On behalf of the IONIQ Sciences Board of Directors, we are delighted to welcome Mr. Dorny to the Board. We believe that his deep understanding of our life science business and proven financial acumen with companies large and small will greatly help us achieve our goals. Mr. Dorny’ s contributions to our company over the pas..." |
|
| 07/14/2021 |
8-K
| Quarterly results |
| 05/28/2021 |
8-K
| Quarterly results |
| 05/28/2020 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits|
Docs:
|
"ProLung announces corporate name change to IONIQ Sciences to reflect expanded early cancer detection strategy Salt Lake City, UT, May 27, 2020 – IONIQ Sciences Inc. , which is changing the cancer landscape with a modern multi-cancer screening technology using its non-invasive Electrical Impedance Analytics technology and a proprietary algorithm, announced it is changing its name from ProLung, Inc. to IONIQ Sciences, Inc. . The new corporate name – IONIQ Sciences – reflects its mission to dramatically improve the cancer landscape with a modern solution for the early detection of multiple cancers thereby expanding the therapeutic window, significantly improving survivability, and reducing the cost of healthcare. IONIQ Sciences remains fully committed to gaining U.S. FDA regulatory clearance ...",
"IONIQ Sciences announces institutional offering Salt Lake City, UT, May 28, 2020 – IONIQ Sciences Inc. , announced it is initiating an institutional private equity offering on the heels of receiving ‘Breakthrough Device Designation’ from the U.S. FDA for its lung cancer test. IONIQ Sciences has also re-branded from ProLung, Inc. to IONIQ Sciences, Inc. to reflect its mission to dramatically improve the cancer landscape with a modern solution for the early detection of cancer thereby expanding the therapeutic window, significantly improving survivability, and reducing the cost of healthcare. Proceeds from the offering are intended to fund the company’ s expansion into developing additional single cancer tests and a multi-cancer screen. The securities to be offered in the institutional..." |
|
| 05/22/2020 |
8-K
| Unregistered Sales of Equity Securities |
| 03/10/2020 |
8-K
| Quarterly results |
| 02/26/2020 |
8-K
| Quarterly results |
| 02/13/2020 |
8-K
| Quarterly results |
| 02/12/2020 |
8-K
| Quarterly results |
| 11/27/2019 |
8-K
| Other Events, Financial Statements and Exhibits |
| 11/26/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"ProLung Announces Change to its Board of Directors Salt Lake City, UT, November 26, 2019 – ProLung, Inc. , which is focused on reducing the time to diagnosis for lung cancer patients, announced that Robert W. Raybould has stepped down from the Board after approximately eight years of valuable service to the Company. Mr. Jared Bauer, Chief Executive Officer, stated, “On behalf of the ProLung employees and Directors, we sincerely thank Mr. Raybould for his incredibly thoughtful service as a trusted advisor and Director through the years. Mr. Raybould has been an unwavering friend of ProLung as an investor for nearly a decade and as a Director since 2012. During his tenure on the Board, he held numerous positions including Vice Chair most recently. I firmly believe that ProLung owes Mr. Raybo..." |
|
| 10/03/2019 |
8-K
| Quarterly results |
| 08/12/2019 |
8-K
| Appointed a new director |
| 08/02/2019 |
8-K
| Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits |
| 06/12/2019 |
8-K
| Appointed a new director|
Docs:
|
"ProLung Announces Changes to its Board of Directors and Leadership Team to Enhance its Medtech Expertise Salt Lake City, UT, June 12, 2019 – ProLung, Inc. , which is focused on reducing the time to diagnosis for lung cancer patients, announced the appointments of Messers. Jim Hogan, David Nielsen and Don Patterson to enhance the medtech expertise and general management leadership on the Board, while J. Scott Nixon and Mark Anderson have stepped down. ProLung has also transitioned its Chief Scientific Officer, Dr. Rex Yung, to its Chief Medical Officer while its former Chief Medical Officer, Dr. Jeff O’ Driscoll, will continue on with the Company as a consultant. The Board sincerely thanks Messers. Nixon, Anderson and O’ Driscoll for their dedicated service to ProLung and welcomes the three...",
"Change to Board of Directors" |
|
| 12/11/2018 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 11/06/2018 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits |
| 10/25/2018 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events |
| 10/23/2018 |
8-K
| Other Events, Financial Statements and Exhibits |
| 10/02/2018 |
8-K
| Quarterly results |
| 10/01/2018 |
8-K
| Quarterly results |
| 09/19/2018 |
8-K
| Other Events, Financial Statements and Exhibits |
| 09/13/2018 |
8-K
| Other Events, Financial Statements and Exhibits |
| 09/11/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/27/2018 |
8-K
| Other Events, Financial Statements and Exhibits |
| 08/15/2018 |
8-K
| Other Events, Financial Statements and Exhibits |
| 08/03/2018 |
8-K
| Appointed a new director |
| 06/29/2018 |
8-K
| Resignation/termination of a director |
| 11/14/2017 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 10/13/2017 |
8-K
| Quarterly results |
| 07/19/2017 |
8-K
| Form 8-K - Current report: |
|
|
|